Shogo Nakamoto1, Junichiro Watanabe2, Shoichiro Ohtani3, Satoshi Morita4, Masahiko Ikeda5. 1. Department of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan b07m1050z@yahoo.co.jp. 2. Department of Breast Oncology, Shizuoka Cancer Center, Shizuoka, Japan. 3. Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. 4. Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. 5. Department of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Fukuyama, Japan.
Abstract
BACKGROUND: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer is unclear. PATIENTS AND METHODS: We retrospectively investigated 301 patients with HER2- ABC who received first-line chemotherapy from January 2011 to December 2016. RESULTS: We included 114 patients who received PB and 187 patients who received other chemotherapies. After propensity score matching, the PB group showed a significantly superior overall response rate (77.8% vs. 38.9%, p<0.0001) and median time to treatment failure (7.3 vs. 5.9 months, p=0.035). In subgroup analyses, PB improved the median overall survival of patients with pleural lesions or pulmonary lymphangiopathy (not reached vs. 18.9 months, p=0.037), and of patients with three or more metastatic sites without liver metastases, (48.0 vs. 27.3 months, p=0.015). CONCLUSION: Compared with conventional chemotherapy, PB improved the overall response rate and time to treatment failure in patients with HER2- advanced breast cancer and improved overall survival in some patient subgroups. Copyright
BACKGROUND: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with humanepidermal growth factor receptor 2-negative (HER2-) advanced breast cancer is unclear. PATIENTS AND METHODS: We retrospectively investigated 301 patients with HER2- ABC who received first-line chemotherapy from January 2011 to December 2016. RESULTS: We included 114 patients who received PB and 187 patients who received other chemotherapies. After propensity score matching, the PB group showed a significantly superior overall response rate (77.8% vs. 38.9%, p<0.0001) and median time to treatment failure (7.3 vs. 5.9 months, p=0.035). In subgroup analyses, PB improved the median overall survival of patients with pleural lesions or pulmonary lymphangiopathy (not reached vs. 18.9 months, p=0.037), and of patients with three or more metastatic sites without liver metastases, (48.0 vs. 27.3 months, p=0.015). CONCLUSION: Compared with conventional chemotherapy, PB improved the overall response rate and time to treatment failure in patients with HER2- advanced breast cancer and improved overall survival in some patient subgroups. Copyright
Authors: Priti S Hegde; Adrian M Jubb; Dafeng Chen; Nicole F Li; Y Gloria Meng; Coen Bernaards; Rebecca Elliott; Stefan J Scherer; Daniel S Chen Journal: Clin Cancer Res Date: 2012-11-20 Impact factor: 12.531
Authors: Antonio Llombart-Cussac; Xavier Pivot; Laura Biganzoli; Hernan Cortes-Funes; Kathleen I Pritchard; Jean-Yves Pierga; Ian Smith; Christoph Thomssen; Stefanie Srock; Miguel Sampayo; Javier Cortes Journal: Breast Date: 2014-07-19 Impact factor: 4.380
Authors: David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: T Brodowicz; I Lang; Z Kahan; R Greil; S Beslija; S M Stemmer; B Kaufman; L Petruzelka; A Eniu; R Anghel; K Koynov; D Vrbanec; T Pienkowski; B Melichar; S Spanik; S Ahlers; D Messinger; M J Inbar; C Zielinski Journal: Br J Cancer Date: 2014-09-30 Impact factor: 7.640